Total Payments
$3,952
2024 Payments
$462.81
Companies
17
Transactions
224
Medicare Patients
5,058
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$3,931 (99.5%)
Education$21.21 (0.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,931 | 222 | 99.5% |
| Education | $21.21 | 2 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,902 | 101 | $0 (2024) |
| Theravance Biopharma, Inc. | $677.47 | 45 | $0 (2018) |
| Gilead Sciences, Inc. | $539.68 | 38 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $249.87 | 10 | $0 (2022) |
| ViiV Healthcare Company | $148.70 | 8 | $0 (2023) |
| Cumberland Pharmaceuticals, Inc. | $78.52 | 4 | $0 (2023) |
| Allergan Inc. | $66.81 | 4 | $0 (2019) |
| AIMMUNE THERAPEUTICS, INC. | $63.92 | 3 | $0 (2024) |
| Astellas Pharma US Inc | $62.32 | 3 | $0 (2024) |
| Molnlycke Health Care US, LLC | $27.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $462.81 | 23 | Merck Sharp & Dohme LLC ($239.03) |
| 2023 | $460.20 | 23 | Merck Sharp & Dohme LLC ($211.70) |
| 2022 | $477.04 | 26 | Merck Sharp & Dohme LLC ($258.20) |
| 2021 | $314.00 | 17 | Merck Sharp & Dohme Corporation ($144.14) |
| 2020 | $180.41 | 8 | Merck Sharp & Dohme Corporation ($75.26) |
| 2019 | $349.68 | 20 | Merck Sharp & Dohme Corporation ($191.10) |
| 2018 | $706.66 | 45 | Merck Sharp & Dohme Corporation ($323.68) |
| 2017 | $1,001 | 62 | Merck Sharp & Dohme Corporation ($458.56) |
All Payment Transactions
224 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.89 | General |
| 10/16/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.94 | General |
| 09/04/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/24/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $26.41 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.25 | General |
| 06/26/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.65 | General |
| 05/15/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: GI | ||||||
| 05/15/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.40 | General |
| 04/23/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $28.93 | General |
| Category: Infectious Diseases | ||||||
| 03/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.56 | General |
| 03/27/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.19 | General |
| 03/20/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: GI | ||||||
| 03/12/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/28/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: VIROLOGY | ||||||
| 02/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.62 | General |
| 02/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.56 | General |
| 12/12/2023 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/06/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: ANTIBIOTIC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,323 | 4,127 | $521,285 | $292,836 |
| 2022 | 13 | 1,182 | 3,351 | $438,685 | $228,470 |
| 2021 | 11 | 1,343 | 3,875 | $523,455 | $286,924 |
| 2020 | 10 | 1,210 | 3,691 | $477,415 | $267,080 |
Total Patients
5,058
Total Services
15,044
Medicare Billing
$1.1M
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 279 | 2,146 | $236,235 | $130,127 | 55.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 263 | 336 | $84,010 | $44,295 | 52.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 133 | 482 | $69,680 | $43,873 | 63.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 239 | 573 | $63,030 | $36,814 | 58.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 89 | 160 | $25,640 | $14,832 | 57.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 62 | $12,405 | $5,994 | 48.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 57 | 81 | $8,910 | $4,923 | 55.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 61 | 73 | $5,475 | $2,839 | 51.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $4,200 | $2,640 | 62.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 98 | 140 | $4,200 | $2,439 | 58.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 20 | 25 | $4,000 | $2,351 | 58.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 19 | 28 | $3,500 | $1,709 | 48.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 368 | 2,099 | $231,030 | $114,795 | 49.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 251 | 311 | $77,830 | $45,774 | 58.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 125 | 311 | $49,560 | $24,265 | 49.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 164 | 259 | $28,490 | $16,079 | 56.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 84 | 147 | $23,520 | $12,547 | 53.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 38 | 46 | $9,200 | $4,697 | 51.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 48 | $5,280 | $2,948 | 55.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $4,600 | $2,843 | 61.8% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 40 | 42 | $3,150 | $1,639 | 52.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 14 | 14 | $2,155 | $1,245 | 57.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 24 | $1,920 | $724.50 | 37.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 11 | 12 | $1,500 | $666.48 | 44.4% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 15 | 15 | $450.00 | $246.72 | 54.8% |
About Dr. David Weber, MD
Dr. David Weber, MD is a Specialist healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144283037.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Weber, MD has received a total of $3,952 in payments from pharmaceutical and medical device companies, with $462.81 received in 2024. These payments were reported across 224 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($3,931).
As a Medicare-enrolled provider, Weber has provided services to 5,058 Medicare beneficiaries, totaling 15,044 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Pittsburgh, PA
- Active Since 04/11/2006
- Last Updated 11/21/2012
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1144283037
Products in Payments
- VIBATIV (Drug) $700.60
- DIFICID (Drug) $516.80
- ZERBAXA (Drug) $448.47
- PREVYMIS (Drug) $356.03
- XARELTO (Drug) $249.87
- CUBICIN RF (Drug) $248.64
- NOXAFIL (Drug) $144.03
- DOVATO (Drug) $81.40
- VOWST (Biological) $80.03
- Vibativ (Drug) $55.39
- JULUCA (Drug) $47.83
- Cresemba (Drug) $47.22
- AVYCAZ (Drug) $36.88
- PNEUMOVAX 23 (Biological) $33.60
- ZINPLAVA (Biological) $31.44
- DALVANCE (Drug) $29.93
- ISENTRESS (Drug) $28.90
- Mepilex Border Ag (Device) $27.00
- NUZYRA (Drug) $24.92
- Yupelri (Drug) $24.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Pittsburgh
Dr. Lawrence Crossett, Md, MD
Specialist — Payments: $5.3M
Specialist $5.3M
Dr. James Bradley, Md, MD
Specialist — Payments: $5.0M
Specialist $5.0M
Darrell Triulzi
Specialist — Payments: $3.3M
Specialist $3.3M
Dr. Mark Yazer, Md, MD
Specialist — Payments: $2.4M
Specialist $2.4M
Lirong Qu
Specialist — Payments: $2.4M
Specialist $2.4M
Dr. Miguel Regueiro, Md, MD
Specialist — Payments: $1.4M
Specialist $1.4M